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Background: Intestinal coeliac auto-antibodies are the marker of coeliac disease (CD). Since the determination
of these antibodies is still not widely available, we used immunoassays to identify the most suitable technol-
ogy for revealing intestinal auto-antibodies in the wide clinical spectrum of CD.
Methods: Intestinal auto-antibodies have been prospectively investigated in CD suspected children using two
immunoassays: intestinal-deposits of IgA anti-tissue transglutaminase antibodies (anti-tTG) and biopsy-cul-
ture IgA anti-endomysium (AEA). Intestinal IgM antibodies have been determined in IgA-deﬁcient subjects.
Findings: Two-hundred and twenty-one suspected CD patients were enrolled. Intestinal antibodies were
tested positive for both assays in classical CD patients (n = 178) with villous atrophy and positive serum-CD
antibodies, potential CD patients (n = 16) with normal intestinal mucosa and positive serum-CD antibodies,
and pre-potential CD patients (n = 14) with normal intestinal mucosa and negative serum-CD antibodies. In
13/221 with normal intestinal mucosa, negative CD-serum antibodies and negative intestinal antibodies CD
has been excluded. All classical, 14/16 potential and 11/14 pre-potential CD patients on gluten-free diet
(GFD) improved their symptoms. In 9/11 pre-potential patients intestinal antibodies disappeared on GFD.
Both assays were negative in 69/71 control subjects. The two assays showed high diagnostic sensitivity
(100%) and speciﬁcity (99%).
Interpretation: Intestinal CD-antibodies make prompt diagnosis in the wide clinical spectrum of CD reducing
the delay in diagnosis and treatment, especially in pre-potential CD patients. The easy handling biopsy cul-
ture assay is an effective diagnostic tool which should be carried out by any gastroenterology unit to recog-
nize all CD clinical manifestations.
Funding: Interreg Central-Europe, IRCCS “Burlo Garofolo”.
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Coeliac disease (CD) is an intestinal auto-immune disorder
induced by gluten ingestion in genetically susceptible individuals
and characterized by small-bowel villous atrophy. Gluten induces a
speciﬁc immune response characterized by the production of auto-
antibodies against the tissue transglutaminase (anti-tTG) [1]. These
auto-antibodies are produced by intestinal B-cells and bind to the tis-
sue transglutaminase protein in the early phases of the disease, whenthe duodenal mucosa is still normal and the serum auto-antibodies
are not detectable [25]. In symptomatic patients with positive-
serum antibodies and villous atrophy, the CD diagnostic criteria are
fulﬁlled and the diagnosis of classical CD is straightforward. However,
thanks to greater awareness of CD, there is an increasing number of
symptomatic patients with potential CD, who have positive-serum
antibodies despite normal histological intestinal mucosa [68], and
more patients with pre-potential CD, namely negative or ﬂuctuating
serum antibodies and normal intestinal mucosa [4,5,9]. In these two
conditions, it has been observed that the presence of intestinal anti-
tTG antibodies is the only mucosal immunological marker of CD. Sig-
niﬁcantly, these patients, who suffer from gastrointestinal and/or
extra-intestinal symptoms (i.e. anaemia, chronic tiredness,
Research in Context
Evidence before this study
Intestinal anti-tissue transglutaminase antibodies (anti-tTG) are a
speciﬁc marker of coeliac disease (CD) to identify symptomatic
patients without the CD-diagnostic criteria. These auto-antibodies
are currently investigated by using the intestinal anti-tTG deposits
immunoassay. This technique is limited to very few specialized
centres because it requires frozen intestinal samples, special labo-
ratory equipment and highly experienced operators.
Added value of this study
Intestinal CD-antibodies have been investigated in the wide
clinical spectrum of CD by using both intestinal deposits and
biopsy culture assays showing similar results in terms of sensi-
tivity and speciﬁcity. These antibodies have been found not
only in subjects with classical or potential CD but also in symp-
tomatic pre-potential CD with normal intestinal mucosa and
negative serum-CD antibodies. For the ﬁrst time intestinal IgM
antibodies have been investigated by using the biopsy culture
method in IgA-deﬁcient subjects suspected of CD.
Implications of all the available evidence
Biopsy culture is the easy handling assay which any gastroenterol-
ogy unit can use to investigate the intestinal coeliac auto-antibod-
ies in daily clinical practice in all the clinical manifestations of CD.
These auto-antibodies make prompt diagnosis in symptomatic
pre-potential patients who may beneﬁt of a well-founded diagno-
sis reducing both unnecessary medical investigations and delay in
diagnosis and treatment.
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the disappearance of the intestinal mucosal anti-tTG [5,6,10]. Thus, it
is very important to have a speciﬁc, user-friendly immunoassay for
intestinal anti-tTG detection to supplement histology in diagnosing
CD, especially in patients without villous atrophy. Currently, these
auto-antibodies are detected as IgA deposits in distal duodenal biop-
sies by means of double immunoﬂuorescence staining on intestinal
cryosections [11]. Paediatric studies show that these IgA deposits had
the best sensitivity values (100%) in detecting patients with classical
CD, and gave scores ranging from 64% to 100% among patients with
potential CD [11]. In non-coeliac patients the speciﬁcity of mucosal
anti-tTG was between 82 and 100% [11,12].
Unfortunately, this methodology is not yet widely available
because it is a time consuming and expensive analysis requiring fro-
zen intestinal samples, special laboratory equipment and highly
experienced operators. For this reason it has been suggested that in
selected cases the frozen specimens should be sent to centres special-
ized in this immunoassay technique [13].
Another immunological test is to look for intestinal auto-antibod-
ies to CD in the supernatants of cultured intestinal biopsies using the
well-established IgA-anti-endomysium (AEA) assay already widely
applied and standardised for serum IgA AEA determination [14]. This
test is not too demanding because both the biopsy culture and the
detection of the IgA AEA secreted in the supernatant can be per-
formed by using commercial kits. In clinical settings, this test applied
on the distal duodenum mucosa specimens produces very high val-
ues of sensitivity (98%) and speciﬁcity (100%) as well as diagnostic
accuracy (98%) [12,15].
In this prospective pediatric study, we evaluated the reliability of
these two immunoassays for detecting the intestinal IgA CD-antibodiesin both duodenal bulb and distal duodenum mucosa of patients with
classical, potential and pre-potential CD and wemonitored the effects of
GFD in these CD-clinical conditions. In addition, the two assays were
used to search for intestinal IgM in subjects with total IgA deﬁciency,
which are a group at risk of CD.
2. Patients and methods
2.1. Patients and study design
Pediatric patients were prospectively recruited at the Institute for
Maternal and Child Health-IRCCS “Burlo Garofolo” in Trieste (Italy) from
September 2016 to August 2018. Consecutive children undergoing clini-
cally indicated upper gastro-intestinal (GI) endoscopy under deep seda-
tion were enrolled. In this study have been included patients not fulﬁlling
the new ESPGHAN guidelines for a serology based CD diagnosis without
biopsy [16]. Patients suspected of CD, because of suggestive symptoms
and serum CD antibodies positivity, were classiﬁed and diagnosed, after
serological and intestinal immuno-histological evaluations, as classical
and potential CD patients on the basis of international classiﬁcations
[17,18] and as pre-potential CD patients on the basis of preliminary clini-
cal experience [4,5,9,19]. These deﬁnitions are described in detail below:
Classical CD  symptomatic subjects positive for serum anti-tTG and/
or AEA concentrations with intestinal villous atrophy;
Po-
tential CD  symptomatic or asymptomatic subjects positive for serum
anti-tTG and/or AEA concentrations with normal intestinal mucosa;
Pre-potential CD  symptomatic or asymptomatic subjects at risk of CD
(e.g. ﬁrst-degree relatives of CD patients, patients with autoimmune dis-
orders) showing a previous serum CD auto-antibodies positivity con-
verted to negativity at the time of GI endoscopy and with normal
intestinal mucosa. Selected pre-potential CD patients testing positive for
intestinal CD-antibodies and suffering from major symptoms (e.g. failure
to thrive, anaemia, aphtous stomatitis, diarrhoea) were put on GFD and
followed for at least one year. After one year of GFD, these patients were
asked to undergo a second GI endoscopy to verify the disappearance of
intestinal CD-antibodies and to conﬁrm the CD diagnosis.
Children with other GI disorders (such as inﬂammatory bowel dis-
ease, gastritis, eosinophilic oesophagitis) at the diagnosis time or dur-
ing the scheduled follow up were asked to take part in the study as a
control group.
Patients with IgA deﬁciency were included in this study.
Following the ESPGHAN’s recommendations (17), the parents of
children testing positive for serum anti-tTG antibodies, were advised
by their pediatrician not to carry out the gluten-free diet before the
gastrointestinal endoscopy examination.
In all enrolled patients, intestinal CD-antibodies were investigated
in bulb and distal duodenum specimens as anti-tTG deposits and AEA
in biopsy culture supernatant. In patients in whom the intestinal CD-
antibodies were detected by only one of the two immunoassays, a
highly sensitive and speciﬁc phage-display antibody assay was used
to verify the intestinal production of CD auto-antibodies. Written
informed consent was obtained from the parents of the children
enrolled, and the study was approved by the hospital’s independent
ethical committee (IRCCS “Burlo Garofolo” Comitato Indipendente
per la Bioetica, Trieste; CE/V-131).
2.2. Serology tests
Serum IgA anti-tTG antibodies were measured using an ELISA assay
(Eurospital Kit Eu-TG2, Trieste, Italy) following the manufacturer’s
instructions and values higher than 10U/mL were considered positive.
L. De Leo et al. / EBioMedicine 51 (2020) 102567 3Serum IgA AEA were investigated by an indirect immunoﬂuores-
cence method following the manufacturer’s instructions (Eurospital
kit Antiendomysium 96, Trieste, Italy). Brieﬂy, sera were tested
diluted 1:5 on sections of monkey oesophagus as substrate and incu-
bated for 30 min at room temperature. After sections were washed to
remove serum and ﬂuorescein isothiocyanate-labelled rabbit anti-
body against human IgA was incubated for 30 min. Serum samples
were considered positive if a thin ﬂuorescent network appeared
around the smooth muscle ﬁbres.
In patients with selective IgA deﬁciency (total IgA < 5mg/dl)
serum samples were investigated for IgG anti-tTG antibodies and
IgG1 AEA.
2.3. HLA typing
Whole blood was used to test for the presence of the susceptibility
alleles for CD using polymerase chain reaction with allele-speciﬁc
primers that identify HLA DQ2 and DQ8, using the Eu-Gene_Risk kit
(Eurospital, Trieste, Italy).
2.4. Intestinal deposits of anti-tTG antibodies
Intestinal IgA anti-tTG antibodies were investigated in 6 criosections
obtained from both bulb and distal duodenum specimens by using a
previously described immunoassay [3,10]. Brieﬂy, unﬁxed frozen sec-
tions were incubated ﬁrst with monoclonal mouse antibody against tTG
(CUB7402; NeoMarkers Fremont, California, USA) followed by Alexa
ﬂuor 594-conjugated anti-mouse IgG secondary antibody (Thermo
Fisher Scientiﬁc Waltham, Massachussetts, USA), and then with ﬂuores-
cein isothiocyanate-labelled rabbit antibody against human IgA (Dako,
Glostrup, Denmark). Multicolor analysis was performed using an Axio-
plan 2 ﬂuorescence microscope (Carl Zeiss, Oberkochen, Germany)
equipped with the speciﬁc software AxioVision (Carl Zeiss, Oberkochen,
Germany) to localize IgA anti-tTG deposits, which appear as yellow spot
below the basement membrane, along the villous and the crypt, and
aroundmucosal vessels.
In patients with selective IgA deﬁciency, IgM (Dako, glostrup,
Denmark) anti-tTG deposits were investigated as previously
described [20].
Samples were considered positive if at least 2/6 criosections from
bulb or distal duodenum showed yellow spots.
In our experience started in 2010 [21], more than 2000 intestinal
biopsies have been evaluated for both IgA and IgM intestinal anti-tTG
deposits, and intraobserver and interobserver variations have both
been 98% in the detection of the presence or the absence of intestinal
deposits among two investigators.
2.5. Biopsy culture AEA assay
Two intestinal fragments, one from bulb and one from distal duode-
num, were cultured for 72 h at 37 °C in the presence of peptic-tryptic
digest of gliadin (PT-gliadin) following the manufacturer’s instructions
(Eurospital kit Antiendomysium biopsy, Trieste, Italy). The culture
supernatants were collected and stored at20 °C until analysis.
Intestinal IgA AEA secreted into culture supernatants were
detected by an indirect immunoﬂuorescence method following the
manufacturer’s instructions (Eurospital kit Antiendomysium 96,
Trieste, Italy). Brieﬂy, undiluted supernatants were tested on sections
of monkey oesophagus as substrate and incubated for 30 min at
room temperature. After sections were washed to remove superna-
tant and ﬂuorescein isothiocyanate-labelled rabbit antibody against
human IgA was incubated for 30 min. Supernatants were considered
positive if a thin ﬂuorescent network appeared around the smooth
muscle ﬁbres.
Intestinal IgM AEA were investigated in patients with selective
IgA deﬁciency.2.6. Phage display library
Phage-antibody libraries were constructed, as previously
described 5, from the subjects’ distal duodenum biopsy B-lympho-
cytes to search for CD-speciﬁc mucosal anti-tTG antibodies, which
are primarily composed of the IGHV5-51 gene from the VH5 gene
family. Selective IgA IGVH5-51 genes were ampliﬁed from the cDNA
and assembled into single-chain fragment-variable (scFv) fragments
by cloning into the phagemid vector pDAN5. ScFvs recognising
human tTG were selected by afﬁnity chromatography. After three
cycles of selection, 45 clones were screened for reactivity to human
tTG protein by ELISA.
All the serologic, genetic, immunologic and molecular analyses
were evaluated by specialists blinded on the subjects’ clinical data
and not involved in clinical decisions.
2.7. Small bowel mucosal morphology
In each patient, 4 intestinal biopsy specimens were taken by
endoscopy: 2 samples each from the bulb and distal duodenum. The
histologic analysis was based on Marsh Oberhuber’s and Corazza Vil-
lanacci Classiﬁcations [22,23]. An independent specialist (V.V.) evalu-
ated the biopsy samples without prior knowledge of our subjects’
clinical and laboratory data.
2.8. Statistics
Data are reported as mean§standard deviation for continuous
variables and as proportion for categorical variables. The sequential
serum samples were compared using the Wilcoxon signed rank test
for paired data.
McNemar test and Cohen’s kappa were used to evaluate the concor-
dance between intestinal anti-tTG deposits and biopsy culture AEA.
Landis and Koch propose Cohen’s kappa as a method to describe the
degree of concordance: 0.010.20, “weak”; 0.210.40, "fair";
0.410.60, "moderate", 0.610.80, "substantial"; 0.811.00, “almost
perfect” [24]. Sensitivity and speciﬁcity were reported with a conﬁdence
interval of 95%. A value of P< 0.05 was considered signiﬁcant.
3. Results
Two hundred and ninety-two patients were enrolled, of whom
221 (76%) (86 boys and 135 girls; median age 7 years, range 118)
had suspected CD. Seventy-one out of 292 (24%) (50 boys and 21
girls; median age 13 years, 118) had other GI disorders and were
enrolled as the control group.
On the basis of serological data obtained at the time of GI endos-
copy we found 194/221 (88%) suspected CD patients were still posi-
tive for serum IgA anti-tTG antibodies (104§164 U/ml) and/or AEA.
The remaining 27/221 (12%), had seroconverted back to both IgA
anti-tTG and AEA negativity, although they were on gluten-contain-
ing diet. In these last 27 children the positive serum anti-tTG concen-
trations were 18§6 U/ml measured 8§ 2 months (mean value§
standard deviation) before the GI endoscopy.
Among the 194 patients positive for serum CD antibodies on the
basis of histological and immunological data we identiﬁed:
Classical CD  One hundred and seventy-eight symptomatic patients
of 221 (80.5%) (Table 1) tested positive for HLA DQ2/8 haplotype and
for serum IgA anti-tTG antibodies (114§172 U/ml) and/or AEA. Intes-
tinal atrophy and high intraepithelial lymphocytes (IEL) density
(102§49/100 epithelial cells) were observed in all patients, but in 19/
178 (11%) only in the bulb duodenum. Both assays for intestinal IgA
antibodies were positive in all patients (Table 2). In the two patients
out of 178 (1%) who showed IgA deﬁciency and tested positive for
Table 1
Clinical ﬁndings of all the CD study groups and of the control
group.
Clinical ﬁndings Classical cd n = 178
Anaemia 11 (6%)
Diarrhoea 12 (7%)
Aphtous stomatitis 5 (3%)
Asthenia 20 (11%)
Failure to thrive 28 (16%)
Recurrent abdominal pain 61 (34%)
Family history of CD 42 (24%)
IgA deﬁciency 2 (1%)
Thyroiditis 5 (3%)
potential cd n = 16
Diarrhoea 4 (25%)
Failure to thrive 10 (62.5%)
Recurrent abdominal pain 3 (19%)
Family history of CD 4 (25%)
Type 1 diabetes 1 (6%)
pre-potential cd n = 14
Anaemia 1 (7%)
Diarrhoea 4 (25%)
Aphtous stomatitis 2 (14%)
Asthenia 4 (29%)
Failure to thrive 5 (36%)
Recurrent abdominal pain 8 (57%)
Family history of CD 2 (14%)
not conﬁrmed cd n = 13
Anaemia 1 (8%)
Diarrhoea 3 (23%)
Aphtous stomatitis 1 (8%)
Failure to thrive 3 (23%)
Recurrent abdominal pain 8 (61%)
Family history of CD 4 (31%)
IgA deﬁciency 3 (23%)
Thyroiditis 1 (8%)
Type 1 diabetes 1 (8%)
Control group n = 71
Inﬂammatory bowel disease 29 (41%)
Eosinophilic oesophagitis 9 (13%)
Gastritis 17 (24%)
Reﬂux oesophagitis 11 (15%)
Others 5 (7%)
CD, coeliac disease.
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intestinal IgM auto-antibodies were found. All 178 symptomatic
patients were diagnosed as having CD and put on GFD.
Potential CD - Sixteen symptomatic patients (7%) (Table 1) tested
positive for HLA DQ2/8 haplotype, tested positive for serum IgA anti-
tTG antibodies values (14§17 U/ml) and/or AEA, showed normal
both intestinal mucosa and IEL density (14§5/100 epithelial cells).
Both assays for intestinal IgA antibodies gave positive results in all
patients (Table 2). Fourteen out of 16 (87.5%) who had severeTable 2
Sensitivity (Se) and Speciﬁcity (Sp) with 95% conﬁdence interval for intestinal anti-tTG dep
coeliac disease has been excluded.
Intestinal anti-tTG deposits +
Bulb
duodenum
(n)
Diagnostic
indicators
Distal
duodenum
(n)
Diagnostic
indicators
Classical CD n 178 178 Se 100% (97100%) 169 Se 95% (91
Potential CD n 16 16 Se 100% (71100%) 15 Se 94% (70
Pre-potential
CD n 14
13 / 9* /
Not conﬁrmed
CD n 13
0 / 0 /
Control group n 71 1 Sp 99% (92100%) 1 Sp 99% (92
CD, coeliac disease; tTG, tissue transglutaminase; AEA, anti-endomysium antibodies; Se, sen
* 1/4 was tested positive only in distal duodenum.symptoms (failure to thrive, diarrhoea) and/or other autoimmune-
associated disorders (diabetes type 1) were put on GFD.
Among the 27 patients transiently positive for serum CD antibod-
ies and tested negative at the time of GI endoscopy, on the basis of
histological and immunological data, we identiﬁed:
Pre-potential CD  fourteen symptomatic patients (6%) (Table 1)
tested positive for HLA DQ2/8 haplotype, negative for both serum IgA
anti-tTG antibodies (2§ 1 U/ml) and AEA, and showed normal
mucosa and IEL density (12§5/100 epithelial cells). Both assays for
intestinal IgA antibodies were positive in all patients (Table 2). Eleven
out of 14 (62.5%) suffering from major symptoms (anaemia, failure to
thrive, aphtous stomatitis, diarrhoea) were put on GFD.
Not conﬁrmed CD  thirteen patients (6%) (Table 1) tested positive
for HLA DQ2/8 haplotype, negative for both serum IgA anti-tTG anti-
bodies (1.9§ 1 U/ml) and AEA, and showed normal intestinal mucosa
and IEL density (10§5/100 epithelial cells). Intestinal auto-antibodies
were negative in all patients (Table 2). Three/13 (23%) showed IgA
deﬁciency. In these 3 patients, who were negative for both serum IgG
anti-tTG (3§ 2 U/ml) and IgG1 AEA, the intestinal IgM auto-antibod-
ies were not found. All these patients remained on a gluten- contain-
ing diet (GCD).
Control group  the HLA DQ2 or DQ8 haplotype was positive in 19/71
subjects (27%) (Table 1), CD-serum markers were negative in all 71
and no CD-related histologic lesions were found. Both assays for
intestinal IgA antibodies were negative in 69/71 patients (Table 2).
The two control patients testing positive for intestinal CD-antibodies
suffered from eosinophilic oesophagitis. One showed widespread
duodenal anti-tTG deposits and AEA in the culture supernatant, while
in the other who tested negative for HLA DQ2/8 haplotype, only the
AEA assay was positive but limited to the duodenal bulb (Table 2). In
the latter control subject, following our study design, the intestinal
biopsy was then analysed using the phage-display antibody assay
and no IGHV5-51 anti-tTG antibody clones were isolated: the subject
was therefore not considered as being at risk of CD.
The sensitivity of the intestinal anti-tTG deposit immunoassay in
the bulb and distal duodenum was 100% and 95% respectively in clas-
sical CD patients, and 100% and 94% in potential CD patients; speciﬁc-
ity was 99% in both sites (Table 2). Sensitivity in the AEA biopsy
culture immunoassay in the bulb and distal duodenum was 100% and
95% in classical CD patients and of 94% and 100% in potential CD
patients; speciﬁcity was 98% in the bulb and 99% in the distal duode-
num (Table 2).osits and biopsy culture AEA. In this table are not reported the thirteen cases in which
Biopsy culture AEA +
Bulb
duodenum
(n)
Diagnostic
indicators
Distal
duodenum
(n)
Diagnostic
indicators
98%) 178 Se 100% (97100%) 169 Se 95% (9198%)
100%) 15 Se 94% (70100%) 16 Se 100% (71100%)
14 / 9 /
0 / 0 /
100%) 2 Sp 98% (90100%) 1 Sp 99% (92100%)
sibility; Sp, speciﬁcity.
Table 3
Comparison between two diagnostic tests in bulb duodenum.
Intestinal anti-tTG deposits
+ 
Biopsy culture AEA + 207 2 P = 0.56*
K = 0.97 (0.95 
1.00)
 1 82
tTG, tissue transglutaminase; AEA, anti-endomysium antibodies.
* Mc-Nemar test; K=Cohen’s Kappa with 95% conﬁdence interval.
Table 5
Clinical ﬁndings of the 3 CD study groups for the GCD and after 12 months of
GFD.
GCD GFD
Active CD (n = 178)
Anaemia 11 (Hb g/dl 9.5§ 0.4) 11 improved (Hb g/dl
12.1§ 0.6)
Diarrhoea 12 12 resolved
Aphtous stomatitis 5 5 resolved
Asthenia 20 20 disappeared
Failure to thrive 28 28 improved (from 5°
10° to 25° centile)
Recurrent abdominal
pain
61 61 improved/
disappeared
Potential CD (n = 14)
Diarrhoea 4 4 resolved
Failure to thrive 10 10 improved (from 5°
10° to 25° centile)
Recurrent abdominal
pain
3 3 improved/disappeared
Pre-potential CD (n = 11)
Anaemia 1 (Hb g/dl 8.5) 1 improved (Hb g/dl 12)
Diarrhoea 4 4 resolved
Aphtous stomatitis 2 2 resolved
Failure to thrive 5 5 improved (from 5°
10° to 25° centile)
GCD, gluten-containing diet; GFD, gluten-free diet; CD, coeliac disease; Hb,
hemoglobin.
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immunoassay with the AEA biopsy culture method, we obtained an
overall concordance of 99.0% in bulb duodenum specimens (Table 3;
p = 0.56, Mc-Nemar test) and of 99.7% in distal duodenum ones
(Table 4; p = 0.32, Mc-Nemar test). K Cohen was calculated and gave a
value of 0.97, 95% CI: 0.950.99 for bulb and of 0.99, 95% CI:
0.981.00 for distal duodenum.
3.1. Follow-up
After 12 months on GFD, all the patients with classical CD showed
negative serum IgA AEA, a signiﬁcant decrease in serum IgA anti-tTG
concentrations (46§172 vs. 4§ 2 U/ml, P<0.0001) and improvement
in their clinical condition (Table 5). In the patients with IgA deﬁ-
ciency, serum values of IgG anti-tTG (72§60 vs. 4§ 3 U/ml,
P<0.0001) and IgG1 AEA were negative.
Fourteen/16 patients with potential CD were put on GFD: 12
months later, 13/14 (93%) showed negative serum AEA, a signiﬁcant
decrease in serum anti-tTG concentrations (14§17 vs. 2§ 3 U/ml,
P<0.0001] and improved symptoms (Table 5). The remaining contin-
ued to test positive for serum CD antibodies and underwent a second
GI endoscopy. Histological analysis showed normal intestinal mucosa
with an increased IEL density (35§2/100 epithelial cells) and intesti-
nal auto-antibodies were detected throughout the duodenum. The
two potential CD patients who were kept on a GCD but monitored,
continued to test positive for serum IgA anti-tTG and AEA and had
occasional abdominal pain. Both of them refused a second GI endos-
copy to assess the intestinal condition.
After 12 months, the eleven pre-potential CD patients who were fol-
lowing a GFD all showed improvement in their symptoms (Table 5).
They were asked to undergo a second GI endoscopy and 9/11 agreed. In
all nine, normal histological ﬁndings were conﬁrmed with the disap-
pearance of the intestinal auto-antibodies (Fig. 1). The other three pre-
potential CD patients who were being monitored on a GCD continued to
test negative for both serum IgA anti-tTG and AEA with unchanged clin-
ical condition (abdominal pain and asthenia).
The 13 patients, in which CD was not conﬁrmed, continued to test
negative for serum-CD antibodies on GCD with amelioration in their
clinical condition. In particular, abdominal pain, diarrhoea and aph-
tous stomatitis disappeared, and anaemia (Hb 10.5 to 11 g/dl) and
failure to thrive (from 15° to 25° centile) ameliorated.
The control subject suffering from eosinophilic oesophagitis who
tested positive for intestinal auto-antibodies continued to test nega-
tive for serum-CD antibodies on GCD.Table 4
Comparison between two diagnostic tests in distal duodenum.
Intestinal anti-tTG deposits
+ 
Biopsy culture AEA + 194 1 P = 0.32*
K = 0.99 (0.98
1.00)
 0 97
tTG, tissue transglutaminase; AEA, anti-endomysium antibodies.
* Mc-Nemar test; K=Cohen’s Kappa with 95% conﬁdence interval.4. Discussion
In this large pediatric prospective study, the assays for intestinal
anti-tTG deposits and biopsy culture AEA both produced similar
results in terms of sensitivity and speciﬁcity for the diagnosis of CD,
even in those forms of CD in which the intestinal mucosa is normal.
Moreover, as regards detection of CD-speciﬁc intestinal auto-anti-
bodies, the two immunoassays showed an overall concordance of
99.0% in bulb duodenum specimens and of 99.7% in distal duodenum
ones. Interestingly, it was possible to determine the presence of
intestinal IgM antibodies in patients with total IgA deﬁciency not
only by means of the anti-tTG deposit assay [20], but also using the
biopsy culture method. Therefore, the biopsy culture assay simpliﬁes
the search for CD-intestinal auto-antibodies in IgA-deﬁciency disor-
der characterized by a high CD prevalence (9%) [25]. In the daily labo-
ratory practice, intestinal anti-tTG assay requires specialized
personnel and speciﬁc equipment to prepare (cryostat) and analyse
(speciﬁc software) the frozen biopsies. On the contrary the biopsy
culture AEA is based on standardized kits, does not require special-
ized personnel and is less time-consuming making the investigation
of intestinal CD-antibodies widely available. Considering materials,
laboratory equipment and time cost of specialized personnel we esti-
mate a cost of €40 per patient for the biopsy culture AEA assay and of
€100 per patient for the intestinal anti-tTG deposits assay.
Intestinal CD-antibodies were detected in 2 sick control patients
suffering from eosinophilic oesophagitis. Following our study design,
one was considered a false positive, having tested negative for CD-
related HLA DQ2/8 and for phage-display antibody assay. The other
patient who was genetically predisposed to gluten intolerance was
considered at risk of CD but remained negative to serum CD antibod-
ies on GCD. This patient was deemed at risk of CD also given the high
prevalence of CD among subjects with eosinophilic oesophagitis [26].
Of interest, none of the control subjects with chronic inﬂammatory
bowel disease tested positive for intestinal CD-antibodies.
Importantly, by analyzing the duodenal bulb biopsies for both IgA
anti-tTG deposits and culture AEA antibody, we obtained an
increased detection rate of intestinal CD-antibodies. In particular, if
duodenal bulb biopsies had not been performed, the intestinal CD-
antibodies would have been missed in 14/208 (7%) of our diagnosed
CD patients (178 classical CD, 16 potential CD and 14 pre-potential
Fig. 1. Intestinal IgA anti-tTG deposits ((a) yellow spots in sub-epithelium, and (b) around crypts) and intestinal AEA in culture supernatant ((c) ﬂuorescent network) at the diagno-
sis and disappearance of both speciﬁc ﬂuorescent signals ((d),(e) intestinal IgA anti-tTG deposits, and (f): intestinal AEA in culture supernatant) after 12 months of gluten-free diet.
6 L. De Leo et al. / EBioMedicine 51 (2020) 102567CD). This is in agreement with our recent observation [10] in which
10% of CD patients (particularly those positive for anti-tTG serum
concentrations but with low values) showed intestinal antibodies
only in the duodenal bulb while the distal duodenum was completely
negative. In general, intestinal antibodies are measured in distal duo-
denal biopsies and for this reason, false negative results have been
obtained in patients with both classical [27] and potential CD [7].
Moreover, the duodenal bulb is also the site that should be investi-
gated for histological analysis, since at the time of diagnosis, from 2.4
to 10% of untreated CD patients had intestinal lesions conﬁned to the
duodenal bulb both in childhood [2830] and adulthood [31]. In
endoscopic practice, analysis of the duodenal bulb has positive impli-
cations for patients, allowing earlier commencement of GFD and
reducing the number of unnecessary medical investigations associ-
ated with delayed diagnosis of CD [10,31].
More in general, testing for the presence of intestinal CD-antibod-
ies not only made prompt diagnosis of CD possible, but when used
together with histological analysis, enabled us to exclude CD in 6% of
symptomatic genetically predisposed subjects negative for serum
auto-antibodies, even though we are aware that a longer follow-up
of these subjects is necessary.The intestinal anti-tTG antibodies were found not only in subjects
with classical or potential CD but also in symptomatic pre-potential
coeliac disease. One concern about the diagnosis of potential and
pre-potential CD is whether or not a strict GFD is required for these
patients. There is evidence that CD-related clinical conditions (such
as anaemia, diarrhoea and failure to thrive) are associated with glu-
ten-dependent immunological inﬂammation at the intestinal level
even in absence of intestinal atrophic lesions [6,32]. The clinical con-
dition of our patients with potential or pre-potential CD improved on
a GFD, in line with the improvement seen in patients with classical
CD. Moreover, after GFD was commenced, there was a signiﬁcant
decrease in anti-tTG serum concentrations among the patients with
potential CD and the disappearance of intestinal anti-tTG among
patients with pre-potential CD, indicating that the gluten-dependent
immune cascade had been turned off. These observations conﬁrm
that GFD cured CD-associated symptoms in patients testing positive
for intestinal anti-tTG without intestinal lesions, supporting the idea
that is not necessary (or wise) to wait for the onset of severe enterop-
athy before starting the most rational diet-therapy [5,6,9]. On the
other hand [33,34] asymptomatic potential CD patients with intesti-
nal anti-tTG deposits on GCD are more likely to develop intestinal
L. De Leo et al. / EBioMedicine 51 (2020) 102567 7damage than those without. This reinforces the diagnostic value of
this marker that should be investigated in routine diagnostics.
The prevalence of different CD-clinical types in children enrolled
in our study was higher than expected for routine endoscopy prac-
tice. This may have resulted in an overestimate of the prevalence of
potential, and in particular, pre-potential CD, which has been
described here for the ﬁrst time. This was a result of a referral bias to
a centre with a specialist interest in CD recruiting patients from all
the North Italian regions. However, these clinical conditions enabled
us to test the reliability of the two immunological assays in presence
of different versions of CD.
In conclusion, the current diagnostic criteria, based on conventional
histology, are inadequate to identify the whole spectrum of CD that is
much wider than described so far. The intestinal CD auto-antibodies
should be investigated in all suspected CD patients who underwent GI
endoscopy in order to identify potential and pre-potential CD patients.
Regarding the pre-potential condition, multicentre and prospective
studies are urgently needed to conﬁrm the presence and the natural his-
tory of this new version of CD that we have identiﬁed by the intestinal
CD auto-antibodies. Moreover, the biopsy culture AEA assay, that in our
hands seems an effective diagnostic tool, should be applied in real ﬁeld
by any gastroenterology unit to further demonstrate the applicability in
CD routine diagnostics.
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